Altimmune Inc (ALT)       11.7  -0.07 (-0.59%)

11.7  -0.07 (-0.59%)

US02155H2004 - Common Stock - After market: 11.69 -0.01 (-0.09%)

News Image
14 days ago - Altimmune, Inc

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

Presentation to be highlighted in the Best of International Liver Congress...

News Image
a month ago - Altimmune, Inc

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that...

News Image
a month ago - Altimmune, Inc

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr....

News Image
a month ago - Altimmune, Inc

Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr....

News Image
2 months ago - Altimmune, Inc

Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that...

News Image
2 months ago - Market News Video

Altimmune Enters Oversold Territory (ALT)

News Image
3 months ago - Altimmune, Inc

Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity

The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD)...

News Image
4 months ago - Altimmune, Inc

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 million as of December 31,...